Christopher Beckett, DO
Adult Medicine · Williamson, WVNPI 1174575898
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 343 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,664 and has fallen 78.7% since, to $355 in 2025.
Across 343 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$761
- Pfizer$397
- AstraZeneca$349
- Johnson & Johnson$263
- Amgen$225
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,852100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $1,006 |
| AbbVie(2 entities) | 60 | $761 |
| Pfizer | 33 | $397 |
| AstraZeneca | 24 | $349 |
| Johnson & Johnson | 17 | $263 |
| Amgen | 15 | $225 |
| Sanofi-aventis U.S. LLC | 18 | $206 |
| Abbott | 11 | $197 |
| Amarin Pharma, Inc. | 15 | $193 |
| Lilly USA, LLC | 13 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $144 |
| Novartis | 9 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $117 |
| Boehringer Ingelheim | 8 | $99 |
| Bayer | 6 | $96 |
| Endo Pharmaceuticals Inc. | 3 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $61 |
| GSK | 3 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
Too few adult medicine providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 217 | $230,013 |
| MounjaroTirzepatide | 119 | $145,009 |
| EliquisApixaban | 93 | $117,200 |
| JanuviaSitagliptin Phosphate | 48 | $62,617 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $60,977 |
| JardianceEmpagliflozin | 52 | $54,384 |
| FarxigaDapagliflozin Propanediol | 47 | $50,328 |
| TrulicityDulaglutide | 33 | $50,115 |
| XifaxanRifaximin | 15 | $47,833 |
| XareltoRivaroxaban | 43 | $44,872 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $34,525 |
| VascepaIcosapent Ethyl | 59 | $33,852 |
| LinzessLinaclotide | 33 | $31,790 |
| TradjentaLinagliptin | 30 | $31,703 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $22,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,006 | $241,026229 claims |
| Lilly USA, LLCMounjaro, Trulicity | $169 | $195,124152 claims |
| PfizerEliquis | $397 | $117,20093 claims |
| Boehringer IngelheimJardiance, Tradjenta | $99 | $86,08782 claims |
| AstraZenecaFarxiga, Symbicort | $349 | $54,56560 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Multaq, Lantus | $206 | $47,86760 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $117 | $47,83315 claims |
| Johnson & JohnsonXarelto | $263 | $44,87243 claims |
| GSKTrelegy Ellipta | $59 | $34,52535 claims |
| AbbVieLinzess | $761 | $31,79033 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $144 | $17,41915 claims |
| NovartisEntresto | $137 | $15,95312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in West Virginiaon file to place this against a meaningful peer group, so we don't.
Other adult medicine in Williamson
- Nilay ThakerMartinsburg$33K
- Jeffrey KelloggShepherdstown$2K
- Christopher MeyerMorgantown$124
- Katherine KochenbachWheeling$86
- Arthur OlsonSummersville$69
- Bharat AgarwalCharleston$35
- Seth GrahamPrinceton$23
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.